Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial
Tenax Therapeutics, Inc. (TENX)
Last tenax therapeutics, inc. earnings: 11/14 04:31 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.tenaxthera.com
Company Research
Source: Business Wire
15 patients have been randomized83% initial response rate to qualify for randomizationPulmonary capillary wedge pressure (PCWP) was reduced , on average, by 8 mmHg during exercise following the initial levosimendan infusionNo serious drug-related adverse events have been reported to date MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today provided an update on its on-going clinical trial of levosimendan.Enrollment UpdateTenax is conducting a multi-center, double-blind placebo controlled Phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The study is also known as the HELP Trial (Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF). The Company has activated all of
Show less
Read more
Impact Snapshot
Event Time:
TENX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TENX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TENX alerts
High impacting Tenax Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TENX
News
- Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateGlobeNewswire
- Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation ConferenceGlobeNewswire
- Tenax Therapeutics, Inc. (NASDAQ: TENX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Tenax Therapeutics, Inc. (NASDAQ: TENX) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $16.00 price target on the stock.MarketBeat
- Tenax Therapeutics, Inc. (NASDAQ: TENX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $16.00 price target on the stock.MarketBeat
TENX
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- TENX's page on the SEC website